Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)

Giuseppe De Luca*, Sander A. Damen, Cyril Camaro, Edouard Benit, Monica Verdoia, Saman Rasoul, Houng Bang Liew, Jawed Polad, Wan A. Ahmad, Robaayah Zambahari, Sonja Postma, Elvin Kedhi, Harry Suryapranata

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

68 Citations (Web of Science)

Abstract

Aims: The optimal duration of DAPT in ACS patients treated with DES is still unclear. Therefore, the aim of the current study was to investigate a short versus a standard 12-month DAPT regimen in ACS patients undergoing new-generation DES implantation.

Methods and results: REDUCE was a prospective, open-label, multicentre, investigator-initiated study that randomised 1,496 ACS patients after treatment with the COMBO stent to either three (n=751) or 12 months (n=745) of DAPT. The primary study endpoint was a composite of all-cause mortality, myocardial infarction, stent thrombosis, stroke, target vessel revascularisation and bleeding at 12 months. No difference was observed in the demographic and clinical characteristics between the two groups, except for gender (p=0.01). At one-year follow-up, non-inferiority of three-versus 12-month DAPT in the primary endpoint was met (8.2% vs 8.4%, p(non-inferiority)

Conclusions: The results show that, among ACS patients treated with the COMBO stent, three months is non-inferior to 12 months of DAPT. However, given the numerically higher rates of mortality and ST in the three-month DAPT group, one-year DAPT should still be recommended in ACS until more information becomes available. A three-month DAPT strategy should be considered only if clinically mandated.

Original languageEnglish
Pages (from-to)E990-E998
Number of pages27
JournalEurointervention
Volume15
Issue number11
DOIs
Publication statusPublished - Dec 2019

Keywords

  • ACS/NSTE-ACS
  • drug-eluting stent
  • STEMI
  • BARE-METAL STENTS
  • PRIMARY ANGIOPLASTY
  • ELUTING STENTS
  • METAANALYSIS
  • CLOPIDOGREL
  • TICAGRELOR
  • DURATION
  • SAFETY

Cite this